. . . . . . . . . "Stigler et al. [10] evaluated the effectiveness and tolerability of paliperidone for irritability in ASD. In this 8-week, prospective, open-label study, 21 (84%) of 25 subjects with ASD (mean age, 15.3 years) were considered responders to paliperidone (mean dosage, 7.1 mg/day), based on Clinical Global Impression (CGI)- Improvement and Aberrant Behaviour Checklist-Irritability sub- scale.v" . . . . . . "Children and adolescents (mean age 15.3 years)" . . . "2021-08-24T15:53:59.968337"^^ . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB" . "OB3R4AJAzcgLYJU89jXwDgvKr4Y/lGN5OQBT4er/UENDehVrRFl1l0rM85W8a5TsMo4zZBuLDqF2+loj6iyCP8IpHflxRb4et30kQ/41Crg2APDBuDDMEwhCQAiocHQGAAhOGFMf601fxCaUGTKgD6FYlABDqVGLY0YTutA3f34=" . . "2021-08-24T15:53:59.968337"^^ . . .